Related Experiment Video
Updated: Aug 6, 2025

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Persistence is key: Refining immunotherapy response prediction
Michelle Leung1, Nicholas McGranahan2
1Cancer Genome Evolution Research Group, University College London Cancer Institute, London, UK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, University College London Cancer Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Abstract:
Tumor mutation burden (TMB) is a proven, but imperfect, immune checkpoint blockade (ICB) response-predictor. Recently in Nature Medicine, Niknafs et al. demonstrate that persistent mutation burden, a subset of TMB, is an improved metric to predict patient ICB therapy outcome.

